Evidence map›Paper›PMID 35350562›Full record

ArticleFrontiers in oncology2022

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy.

Lisi Zeng, Xubo Huang, Yun Tian, Jinxia Huang, Huiyan Liu, Juncai Wen, Kaihua Liu, Yang Shao, Jiali Luo, Hongsheng Tang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Lisi ZengAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Xubo HuangAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Yun TianDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Jinxia HuangAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Huiyan LiuAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Juncai WenDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Kaihua LiuMedical Department, Nanjing Geneseeq Technology Inc., Nanjing, China.
Yang ShaoMedical Department, Nanjing Geneseeq Technology Inc., Nanjing, China.
Jiali LuoAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Hongsheng TangDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Quanxing LiaoDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Ziying LeiDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Weiwen CuiDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, United States.
Qianghua XiaAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Tianpei GuanDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Jin LiAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Shuzhong CuiDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University · CNUniversity of California, Berkeley · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC. Methods: Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study. Results: The tumor mutational burden (TMB) was significantly higher in the group of patients with a better response to HIPEC treatment than that of the others. Kaplan-Meier survival curve showed that patients with high TMB had a significantly longer survival time than that in patients with low TMB. This discovery was validated in the replication cohort. Genes bearing mutations recurrently and selectively in patients with better response to HIPEC were found in the two cohorts. Conclusion: We found that higher TMB is significantly associated with better response to HIPEC. Our results provide useful hints for prognostic stratification of HIPEC treatment.

Indexed as

biomarkergastric cancerhyperthermic intraperitoneal chemotherapysurvivaltumor mutational burden

Identifiers

PMID35350562
PMCPMC8958003
OpenAlexW4220903326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.